Evogene EVGN Stock
Evogene Price Chart
Evogene EVGN Financial and Trading Overview
| Evogene stock price | 1.11 USD |
| Previous Close | 0.78 USD |
| Open | 0.77 USD |
| Bid | 0.77 USD x 800 |
| Ask | 0.77 USD x 900 |
| Day's Range | 0.74 - 0.8 USD |
| 52 Week Range | 0.55 - 1.3 USD |
| Volume | 235.64K USD |
| Avg. Volume | 81.1K USD |
| Market Cap | 32.07M USD |
| Beta (5Y Monthly) | 0.827397 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.89 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 1.5 USD |
EVGN Valuation Measures
| Enterprise Value | 11.71M USD |
| Trailing P/E | N/A |
| Forward P/E | -1.675 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 15.423453 |
| Price/Book (mrq) | 1.4510357 |
| Enterprise Value/Revenue | 5.633 |
| Enterprise Value/EBITDA | -0.491 |
Trading Information
Evogene Stock Price History
| Beta (5Y Monthly) | 0.827397 |
| 52-Week Change | 2.63% |
| S&P500 52-Week Change | 19.24% |
| 52 Week High | 1.3 USD |
| 52 Week Low | 0.55 USD |
| 50-Day Moving Average | 0.61 USD |
| 200-Day Moving Average | 0.73 USD |
EVGN Share Statistics
| Avg. Volume (3 month) | 81.1K USD |
| Avg. Daily Volume (10-Days) | 158.93K USD |
| Shares Outstanding | 41.62M |
| Float | 40.78M |
| Short Ratio | 3.4 |
| % Held by Insiders | 2.03% |
| % Held by Institutions | 3.38% |
| Shares Short | 223.79K |
| Short % of Float | 0.54% |
| Short % of Shares Outstanding | 0.54% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -1235.30% |
| Gross Margin | 48.62% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -27.58% |
| Return on Equity (ttm) | -66.61% |
Income Statement
| Revenue (ttm) | 2.08M USD |
| Revenue Per Share (ttm) | 0.05 USD |
| Quarterly Revenue Growth (yoy) | 170.50% |
| Gross Profit (ttm) | 766K USD |
| EBITDA | -23868000 USD |
| Net Income Avi to Common (ttm) | -24634000 USD |
| Diluted EPS (ttm) | -0.76 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 28.8M USD |
| Total Cash Per Share (mrq) | 0.69 USD |
| Total Debt (mrq) | 1.64M USD |
| Total Debt/Equity (mrq) | 5.77 USD |
| Current Ratio (mrq) | 5.864 |
| Book Value Per Share (mrq) | 0.531 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -22215000 USD |
| Levered Free Cash Flow (ttm) | -13814250 USD |
Profile of Evogene
| Country | United States |
| State | N/A |
| City | Rehovot |
| Address | 13 Gad Feinstein Street |
| ZIP | 7414002 |
| Phone | 972 8 931 1900 |
| Website | https://www.evogene.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 137 |
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.
Q&A For Evogene Stock
What is a current EVGN stock price?
Evogene EVGN stock price today per share is 1.11 USD.
How to purchase Evogene stock?
You can buy EVGN shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Evogene?
The stock symbol or ticker of Evogene is EVGN.
Which industry does the Evogene company belong to?
The Evogene industry is Biotechnology.
How many shares does Evogene have in circulation?
The max supply of Evogene shares is 6.67M.
What is Evogene Price to Earnings Ratio (PE Ratio)?
Evogene PE Ratio is now.
What was Evogene earnings per share over the trailing 12 months (TTM)?
Evogene EPS is -2.89 USD over the trailing 12 months.
Which sector does the Evogene company belong to?
The Evogene sector is Healthcare.
Evogene EVGN included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 17382.94 USD — |
+1.26
|
6.5B USD — | 17110.72 USD — | 17404.49 USD — | — - | 6.5B USD — |
| NASDAQ Global Market Composite NQGM | 1839.71 USD — |
-3.16
|
— — | 1825.54 USD — | 1881.06 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 923.51 USD — |
-0.73
|
— — | 917.75 USD — | 925.61 USD — | — - | — — |
- {{ link.label }} {{link}}